<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28235">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739152</url>
  </required_header>
  <id_info>
    <org_study_id>TRIAGE</org_study_id>
    <nct_id>NCT02739152</nct_id>
  </id_info>
  <brief_title>TRIAGE: TRIage of Sepsis At emerGency dEpartment</brief_title>
  <acronym>TRIAGE</acronym>
  <official_title>TRIAGE: TRIage of Sepsis At emerGency dEpartment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Investigation Clinique, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioMérieux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is a serious systemic disease defined as a combination of Systemic Inflammation
      Response Syndrome (SIRS) plus a confirmed or suspected infection. Untreated or inadequately
      treated cases can lead to severe sepsis or septic shock; being characterized by high
      mortality and morbidity.

      Symptoms and signs of sepsis are variable and this makes clinical recognition and assessment
      very difficult in particular on Emergency Department (ED) patients due to their infectious
      illness background and the frequent comorbidities. Also, the severity of the condition may
      not be apparent at initial contact with ED personnel: patients may arrive at ED with mild
      clinical manifestation and rapidly progress to critical illness, or rather at the opposite
      others have benign evolution despite a similar symptoms. In these conditions, the main
      challenge of ED clinicians is differentiating mild infections from life-threatening ones in
      the heavy workload of ED environment Objective of TRIAGE project is to identify and validate
      biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency
      Department.

      Targeted population is adult patients freshly admitted at ED, whom blood samples will serve
      to validate candidate markers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>patient worsening within a time frame of 72h,change, from day of inclusion, in Sequential Organ Failure Assessment score (SOFA) and/or sepsis classification</measure>
    <time_frame>Up to 72 hours after admission</time_frame>
    <description>A biostatistics analysis will be led in two steps. The first analysis or &quot;train set&quot; will be conducted on the first 150 patients enrolled, estimated size to reach statistical performance. The objective is to identify markers associated with clinical worsening of patients and decide on a model by selecting the best combination of markers. In a second time, performance will be confirmed during the &quot;test set&quot;. The number of samples to be tested depends on the target performance calculated with the area under the Receiver operating characteristic (ROC) curve (AUC). We decided to aim for an AUC of 0.75, based on the performance described in the literature for some triage score as MEDS (Mortality in Emergency Department Sepsis) or those associated with Lactate concentration used as marker of sepsis deterioration in ED</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient status at D28 (alive or death)</measure>
    <time_frame>Up to 28 days after admission</time_frame>
    <description>A biostatistics analysis will be led in two steps. The first analysis or &quot;train set&quot; will be conducted on the first 150 patients enrolled. The objective is to identify markers associated with mortality at day 28. In a second time, the performance will be confirmed during the &quot;test set&quot;.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">515</enrollment>
  <condition>Sepsis</condition>
  <condition>Severe Sepsis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient freshly admitted to Emergency department
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged over 18 years

          -  Patient with a single acute infection site suspected or confirmed by the clinician on
             clinical or paraclinical manifestations.

          -  Patient admitted to ED with at least two systemic inflammatory response syndrome
             (SIRS) criteria

          -  Patient with symptoms for less than 72 hours upon arrival to the emergency
             department.

          -  Patient requiring according to physician judgment of hospitalization for at least 48
             hours for his septic episode

          -  Patient having been informed of the conditions of the study and having signed the
             informed consent form

        Exclusion Criteria:

          -  Patient arrived in an emergency room for over 6 hours.

          -  Patient with septic shock upon arrival to the ED Patient with acute organ failure on
             arrival at emergencies other than septic.

          -  Patient hospitalized in the week before inclusion.

          -  Patient immunocompromised (HIV, transplanted, patients undergoing chemotherapy,
             patients receiving treatment&gt; 20 mg / day of prednisolone or equivalent).

          -  Patient with known pathology among non-infectious pathologies potentially associated
             with SIRS

          -  Patient diagnosed with sepsis within 30 days before the date of inclusion.

          -  Patient has already been included in the study.

          -  Minor Person.

          -  Person refusing to sign the written consent form.

          -  Pregnant woman parturient or nursing.

          -  Patient with no social security insurance, with restricted liberty or under legal
             protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine VALLEJO, MD</last_name>
    <phone>+33 (0)4 05 55 05 64 91</phone>
    <email>Christine.Vallejo@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Angélique Cazalis</last_name>
    <phone>+33 (0) 4 78 87 22 11</phone>
    <email>marie-angelique.cazalis@biomerieux.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc - UCL</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck Verschuren, M.D., PhD</last_name>
      <email>franck.verschuren@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Franck Verschuren, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Angoulême</name>
      <address>
        <city>Angoulême</city>
        <zip>16959</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois JARDIN, MD</last_name>
      <email>fjardin@chu-besancon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Claire MONTINI, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thibaut DESMETTRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Brive La Gaillarde</name>
      <address>
        <city>Brive La Gaillarde</city>
        <zip>19100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques REMIZE, MD</last_name>
      <email>jacques.remize@ch-brive.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques REMIZE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental - Hôpital La Roche-sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline ANNOOT, MD</last_name>
      <email>caroline.annoot@chd-vendee.fr</email>
    </contact>
    <contact_backup>
      <last_name>Valérie DESROYS du ROURE, MD</last_name>
      <email>valerie.desroysduroure@chd-vendee.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Caroline ANNOOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique (CIC)-CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine VALLEJO, MD</last_name>
      <phone>+33 (0)4 05 55 05 64 91</phone>
      <email>Christine.Vallejo@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Lafon, MD</last_name>
      <email>thomas.lafon@chu-limoges.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christine VALLEJO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno FRANCOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent JACQUIN, MD</last_name>
      <email>laurent.jacquin@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marion DOUPLAT, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Karim TAZAROURTE, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anaïs COLONNA, MD</last_name>
      <email>anaiscolonna@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anaïs COLONNA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustapha SEBBANE, M.D., PhD</last_name>
      <email>m-sebbane@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Mustapha SEBBANE, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance publique - Hôpitaux de Paris Hopital de Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saïd LARIBI, MD, PhD</last_name>
      <email>s.laribi@chu-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Valerie GISSOT, MD</last_name>
      <email>valerie.gissot@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Saïd LARIBI, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>March 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Severe sepsis</keyword>
  <keyword>Infections</keyword>
  <keyword>Worsening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
